cytochrome P450 family 2 subfamily B member 7, pseudogeneGenealiases: []
Q-omics provides the consensus-scored CYP2B7P profile across patient tissues and cancer cell-line models. CYP2B7P expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, CYP2B7P is differentially expressed in 11, with the highest sampling consensus in COAD. Additionally, CYP2B7P RNA expression shows 20,072 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight UVM, COAD, and LSCC as cancer lineages where CYP2B7P shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CYP2B7P — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CYP2B7P survival associations across molecular data types. CYP2B7P RNA expression shows survival associations in the most cancer types (23), followed by mutation status (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CYP2B7P RNA expression–survival associations across cancer types. High CYP2B7P expression shows unfavorable associations in LUSC, STAD and ACC, but favorable associations in UVM, HNSC and LUAD. The UVM Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for CYP2B7P RNA expression.
This table summarizes CYP2B7P tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for CYP2B7P. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CYP2B7P shows lower tumor expression in COAD, LUAD, LUSC and KICH and higher tumor expression in BRCA and THCA. The COAD box plot shows higher CYP2B7P RNA expression in normal versus tumor tissue (log2 FC = −1.498, t-test p < 0.001).
This table shows molecular features associated with CYP2B7P in patient tissues and cancer cell lines. In patient samples, CYP2B7P shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, CYP2B7P RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LARGE_INTESTINE, while CRISPR and shRNA rows add functional-dependency signals in LUNG_NSCLC_LUSC and NCI60_ALL.
